Xenon Pharmaceuticals Inc.
XENE
Clasificación en acciones
#4417
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Precio por acción
$36.43
Capitalización bursátil
$3.53B
Cambio (1 día)
3.85%
Cambio (1 año)
-16.13%
País
CA
Comercio Xenon Pharmaceuticals Inc. (XENE)
Categoría
Healthcare
Número de acciones en circulación de Xenon Pharmaceuticals Inc. (XENE)
Número de acciones en circulación al June 2026: 99.61M
Según los últimos informes financieros y el precio de las acciones de Xenon Pharmaceuticals Inc., el número actual de acciones en circulación es 99.61M. Al final de December 2023, la empresa tenía 66.89M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Xenon Pharmaceuticals Inc. (XENE) desde 2011 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 99.61M | 27.88% |
| 2024 | 77.89M | 16.45% |
| 2023 | 66.89M | 10.48% |
| 2022 | 60.54M | 38.77% |
| 2021 | 43.63M | 26.30% |
| 2020 | 34.54M | 33.17% |
| 2019 | 25.94M | 33.53% |
| 2018 | 19.43M | 8.01% |
| 2017 | 17.99M | 16.08% |
| 2016 | 15.49M | 8.48% |
| 2015 | 14.28M | 2.89% |
| 2014 | 13.88M | 52.78% |
| 2013 | 9.09M | 582.58% |
| 2012 | 1.33M | 0.14% |
| 2011 | 1.33M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 154.89% |
US
|
|
| 396.00M | 297.55% |
US
|
|
| 478.91M | 380.79% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -37.57% |
NL
|
